Sandoz Launches Ranluspec Biosimilar In Europe
Nov 12 (Reuters) - SANDOZ GROUP AG SDZ.S:
SANDOZ LAUNCHES RANLUSPEC® (RANIBIZUMAB) IN EUROPE, PROVIDING AN AFFORDABLE TREATMENT OPTION FOR PATIENTS WITH RETINAL DISEASES
RANLUSPEC APPROVED BY EUROPEAN COMMISSION IN FEBRUARY 2026
RANLUSPEC HAS EQUIVALENT EFFICACY AND COMPARABLE SAFETY TO LUCENTIS
HOLDS EXCLUSIVE RIGHTS FOR RANLUSPEC IN EU EXCLUDING GERMANY
COMMERCIALISES EPRUVY (RANIBIZUMAB) IN GERMANY UNDER SEPARATE AGREEMENT
RANLUSPEC COMMERCIALISED BY SANDOZ IN EU EXCLUDING GERMANY
Further company coverage: SDZ.S